Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - eltrombopag olamine, quantity: 15.9 mg (equivalent: eltrombopag, qty 12.5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; mannitol; povidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - revolade is indicated for the treatment of: - paediatric patients with chronic immune thrombocytopaenia (itp) who have failed other treatments and either (a) need an increased platelet concentration for a planned procedure or (b) are at a high risk of bleeding.,- adult patients with chronic itp who have had an inadequate response or are intolerant to corticosteroids and immunoglobulins.,- thrombocytopenia in adult patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.,- severe aplastic anaemia (saa) in combination with standard immunosuppressive therapy for the first-line treatment of adult and paediatric patients 2 years and older.,- adult patients with saa who have had an insufficient response to immunosuppressive therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - eltrombopag olamine, quantity: 95.7 mg (equivalent: eltrombopag, qty 75 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; povidone; magnesium stearate; mannitol; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400 - revolade is indicated for the treatment of: - paediatric patients with chronic immune thrombocytopaenia (itp) who have failed other treatments and either (a) need an increased platelet concentration for a planned procedure or (b) are at a high risk of bleeding.,- adult patients with chronic itp who have had an inadequate response or are intolerant to corticosteroids and immunoglobulins.,- thrombocytopenia in adult patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy.,- severe aplastic anaemia (saa) in combination with standard immunosuppressive therapy for the first-line treatment of adult and paediatric patients 2 years and older.,- adult patients with saa who have had an insufficient response to immunosuppressive therapy.

Kenya - English - Pharmacy and Poisons Board

beacon medicare limited 9/b/2, toyenbee circular road, motijheel, - eltrombopag olamine - tablet - eltrombopag olamine inn equivalent to 25 mg … - eltrombopag

Kenya - English - Pharmacy and Poisons Board

beacon medicare limited 9/b/2, toyenbee circular road, motijheel, - eltrombopag olamine - tablet - eltrombopag olamine inn equivalent to 50 mg … - eltrombopag

Canada - English - Health Canada

novartis pharmaceuticals canada inc - eltrombopag (eltrombopag olamine) - tablet - 25mg - eltrombopag (eltrombopag olamine) 25mg - hematopoietic agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - eltrombopag (eltrombopag olamine) - tablet - 50mg - eltrombopag (eltrombopag olamine) 50mg - hematopoietic agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - eltrombopag (eltrombopag olamine) - tablet - 75mg - eltrombopag (eltrombopag olamine) 75mg - hematopoietic agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - eltrombopag (eltrombopag olamine) - tablet - 12.5mg - eltrombopag (eltrombopag olamine) 12.5mg - hematopoietic agents

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome s.a. - eltrombopag (eltrombopag olamine) - tablets film-coated - 25mg

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - eltrombopag olamine 31.9 mg eqv eltrombopag - tablet, film coated - 25mg - eltrombopag olamine 31.9 mg eqv eltrombopag 25mg